文献速递乳腺MR

动态增强MRI对侧乳腺实质强化与ER阳性/HER2阴性乳腺癌基因组ER通路活性是否相关

Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?
PubMed 文献 · Eur J Radiol · 2019-10-16

该回顾性研究纳入227例连续的单侧浸润性ER阳性/HER2阴性乳腺癌患者,在保乳术前行动态增强MRI,评估健康对侧乳腺实质强化(CPE),并与手术标本的SET指数和ER因子(反映ER通路活性的基因组检测)进行线性回归分析。结果显示CPE与SET指数(R²=0.005)及ER因子(R²=0.0002)均无显著关联;低CPE与高CPE组间仅诊断时年龄有显著差异(P<0.001)。结论认为对侧实质强化与肿瘤来源的ER通路活性无关。

要点

  • 对侧乳腺实质强化(CPE)与肿瘤ER通路基因组活性(SET指数、ER因子)均无显著关联。
  • CPE评估采用既往报道的方法:取晚期强化最高10%区域的平均值。
  • 低CPE与高CPE组间仅诊断时年龄存在显著差异(P<0.001)。

核心结论

  • 动态增强MRI上的对侧乳腺实质强化与肿瘤来源的雌激素受体通路活性无显著关联。

研究设计与样本

  • 回顾性研究,纳入2000至2008年间连续入组的227例单侧浸润性ER阳性/HER2阴性乳腺癌患者,保乳术前行动态增强MRI。

关键影像表现/征象

  • CPE采用既往报道的方法测量健康对侧乳腺实质灌注,即晚期强化最高10%区域的平均值。
  • CPE与SET指数线性回归分析R²=0.005,无显著关联。
  • CPE与ER因子线性回归分析R²=0.0002,无显著关联。
  • 低CPE与高CPE组间仅诊断时年龄有显著差异(P<0.001)。

诊断标准与关键数值

  • CPE定义为健康对侧乳腺实质晚期强化最高10%区域的平均值。
  • SET指数为基于ESR1相关基因的基因组检测,用于估计内分泌治疗的生存获益。
  • ER因子检测其他因素(包括蛋白表达)以评估ER通路活性。

临床应用与阅片要点

  • 阅读乳腺动态增强MRI时,对侧实质强化程度与肿瘤ER通路基因组活性无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To retrospectively explore the relation between parenchymal enhancement of the healthy contralateral breast on dynamic contrast-enhanced magnetic resonance imaging (MRI) and genomic tests for estrogen receptor (ER)-pathway activity in patients with ER-positive/HER2-negative cancer.

METHODS: A subset of 227 consecutively included patients with unilateral invasive ER-positive/HER2-negative breast cancer underwent dynamic contrast-enhanced MRI prior to breast-conserving therapy between 2000 and 2008. Perfusion of the parenchyma in the healthy breast was assessed using a previously reported measure of contralateral parenchymal enhancement (CPE), consisting of the mean of the top-10% late enhancement. ER-pathway activity was assessed from the surgical resection specimen by the previously reported sensitivity to endocrine therapy (SET)-index and ER-factor. The SET-index is a genetic test to estimate survival benefit from endocrine therapy, consisting of genes related to the ESR1 gene. The ER-factor examines other factors as well including protein expression. The relation between CPE and ER-pathway activity was modeled using linear regression.

RESULTS: Patients had a median age of 59 years. CPE was not significantly associated with the SET-index (R-squared = 0.005) nor the ER-factor (R-squared = 0.0002). The only variable significantly different between low and high CPE was age at diagnosis (P < 0.001).

CONCLUSIONS: Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI was not associated with tumor-derived estrogen receptor pathway activity.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. van der Velden BHM, Bismeijer T, Canisius S, et al. Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related? Eur J Radiol. 2019. PMID: 31655316. doi:10.1016/j.ejrad.2019.108705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。